New Indication: Durvalumab for Limited Stage SCLC
Study
Phase 3, randomized, double-blind, placebo-controlled trial, multicenter
|
Limited-stage small-cell lung cancer (LS-SCLC) after chemoradiation
|
Durvalumab vs. placebo
|
Efficacy
Median OS: 55.9 mos vs. 33.4 mos (durvalumab vs. placebo) (HR: 0.73 [0.54-0.98])
|
Median PFS: 16.6 mos vs. 9.2 mos (HR: 0.76 [0.59-0.98])
|
Among 175 pts with measurable disease: Objective response: 30.3% vs. 32.0%
|
Safety
Grade ≥3 AEs: Pneumonitis (3.1% vs. 2.6%), Rash (12.1% vs. 0.3%), Diarrhea (9.3% vs. 0.3%)
|
Serious AEs: 29.8% vs. 24.2% (durvalumab vs. placebo)
|
Discontinuations due to AEs: 16.4% vs. 10.6% (durvalumab vs. placebo)
|
Cheng Y,Spigel RD,Cho BC Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Reviewed by Ulas D. Bayraktar, MD on Dec 6, 2024